X
API Suppliers
US DMFs Filed
0
CEP/COS Certifications
0
JDMFs Filed
0
Other Certificates
0
Other Suppliers
0
0
USA (Orange Book)
Europe
0
Canada
0
Australia
0
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
0
Annual Reports
0
0
Details:
FRUZAQLA (fruquintinib) is the first and only selective inhibitor of all three VEGF receptor kinases approved in the U.S. for previously treated mCRC regardless of biomarker status.
Lead Product(s): Fruquintinib
Therapeutic Area: Oncology Product Name: Fruzaqla
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 26, 2024
Details:
Fruzaqla (fruquintinib) is a selective oral VEGFR inhibitor it plays a pivotal role in blocking tumor angiogenesis. It is being investigated in combination with sintilimab (PD-1 inhibitor) for the treatment of advanced endometrial cancer.
Lead Product(s): Fruquintinib,Sintilimab
Therapeutic Area: Oncology Product Name: Fruzaqla
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Innovent Biologics
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 01, 2024
Details:
Elunate (fruquintinib) is a selective oral inhibitor of VEGF receptors. It is approved in Hong Kong for the treatment of metastatic colorectal cancer.
Lead Product(s): Fruquintinib
Therapeutic Area: Oncology Product Name: Elunate
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 29, 2024
Details:
Fruquintinib is a selective oral VEGFR inhibitor it plays a pivotal role in blocking tumor angiogenesis. It being investigated in combination with sintilimab (PD-1 inhibitor) for advanced renal cell carcinoma in China.
Lead Product(s): Fruquintinib,Sintilimab
Therapeutic Area: Oncology Product Name: HMPL-013
Highest Development Status: Phase II/ Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 12, 2023
Details:
FRUZAQLA (fruquintinib) is the first and only selective inhibitor of all three VEGF receptor kinases approved in the U.S. for previously treated mCRC regardless of biomarker status.
Lead Product(s): Fruquintinib
Therapeutic Area: Oncology Product Name: Fruzaqla
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 08, 2023
Details:
Elunate (fruquintinib) is a highly selective and potent oral inhibitor of VEGFR -1, -2 and -3. VEGFR inhibitors play a pivotal role in blocking tumor angiogenesis and designed to improve kinase selectivity with the intention of minimizing off-target toxicities.
Lead Product(s): Fruquintinib
Therapeutic Area: Oncology Product Name: Elunate
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Takeda Pharmaceutical
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 29, 2023
Details:
Elunate (fruquintinib) is a highly selective and potent oral inhibitor of VEGFR -1, -2 and -3. VEGFR inhibitors play a pivotal role in blocking tumor angiogenesis and designed to improve kinase selectivity with the intention of minimizing off-target toxicities.
Lead Product(s): Fruquintinib,Sintilimab
Therapeutic Area: Oncology Product Name: Elunate
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 20, 2023
Details:
HMPL-013 (fruquintinib) is a highly selective and potent oral inhibitor of VEGFR -1, -2 and -3. VEGFR inhibitors play a pivotal role in blocking tumor angiogenesis and designed to improve kinase selectivity with the intention of minimizing off-target toxicities.
Lead Product(s): Fruquintinib
Therapeutic Area: Oncology Product Name: Elunate
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Hutchmed
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 15, 2023
Details:
HMPL-013 (fruquintinib) is a highly selective and potent oral inhibitor of VEGFR -1, -2 and -3. VEGFR inhibitors play a pivotal role in blocking tumor angiogenesis and designed to improve kinase selectivity with the intention of minimizing off-target toxicities.
Lead Product(s): Fruquintinib
Therapeutic Area: Oncology Product Name: HMPL-013
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Hutchmed
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 25, 2023
Details:
Elunate (fruquintinib) is a highly selective and potent oral inhibitor of VEGFR-1, -2 and -3. VEGFR inhibitors play a pivotal role in blocking tumor angiogenesis. NDA has been acceptance in china for fruquintinib in second-line gastric cancer.
Lead Product(s): Fruquintinib
Therapeutic Area: Oncology Product Name: Elunate
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Eli Lilly
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 17, 2023
Details:
Elunate (fruquintinib) is a highly selective and potent oral inhibitor of VEGFR-1, -2 and -3. VEGFR inhibitors play a pivotal role in blocking tumor angiogenesis.
Lead Product(s): Fruquintinib
Therapeutic Area: Oncology Product Name: Elunate
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 31, 2023
Details:
Under the agreement, Takeda will receive worldwide license to develop and commercialize HMPL-013 (fruquintinib) from HUTCHMED in metastatic CRC and territories outside of mainland China, Hong Kong and Macau. Fruquintinib has been approved in China under the brand name ELUNATE.
Lead Product(s): Fruquintinib
Therapeutic Area: Oncology Product Name: Elunate
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Takeda Pharmaceutical
Deal Size: $1,130.0 million Upfront Cash: $400.0 million
Deal Type: Licensing Agreement March 14, 2023
Details:
Under the agreement, Takeda will receive worldwide license to develop and commercialize HMPL-013 (fruquintinib) from HUTCHMED in metastatic CRC and territories outside of mainland China, Hong Kong and Macau. Fruquintinib has been approved in China under the brand name ELUNATE.
Lead Product(s): Fruquintinib
Therapeutic Area: Oncology Product Name: Elunate
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Takeda Pharmaceutical
Deal Size: $1,130.0 million Upfront Cash: $400.0 million
Deal Type: Licensing Agreement January 23, 2023
Details:
Elunate (fruquintinib) is a highly selective and potent oral inhibitor of VEGFR-1, -2 and -3. VEGFR inhibitors play a pivotal role in blocking tumor angiogenesis. Fruquintinib was designed to improve kinase selectivity to minimize off-target toxicities.
Lead Product(s): Fruquintinib
Therapeutic Area: Oncology Product Name: Elunate
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 19, 2022
Details:
Elunate (fruquintinib) is a highly selective and potent oral inhibitor of VEGFR-1, -2 and -3. Fruquintinib was designed to improve kinase selectivity to minimize off-target toxicities, improve tolerability and provide more consistent target coverage.
Lead Product(s): Fruquintinib,Paclitaxel
Therapeutic Area: Oncology Product Name: Elunate
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 14, 2022
Details:
Elunate (fruquintinib) is a highly selective and potent oral inhibitor of VEGFR-1, -2 and -3. VEGFR inhibitors play a pivotal role in blocking tumor angiogenesis.Fruquintinib is being developed in Combination with Sintilimab for Advanced Renal Cell Carcinoma in China.
Lead Product(s): Fruquintinib,Sintilimab
Therapeutic Area: Oncology Product Name: Elunate
Highest Development Status: Phase II/ Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 27, 2022
Details:
Elunate (Fruquintinib) is a highly selective and potent oral inhibitor of VEGFR-1, -2 and -3. VEGFR inhibitors play a pivotal role in blocking tumor angiogenesis.
Lead Product(s): Fruquintinib
Therapeutic Area: Oncology Product Name: Elunate
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 07, 2022
Details:
Elunate (fruquintinib) is a highly selective and potent oral inhibitor of VEGFR-1, -2 and -3. VEGFR inhibitors play a pivotal role in blocking tumor angiogenesis.
Lead Product(s): Fruquintinib
Therapeutic Area: Oncology Product Name: Elunate
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 23, 2022
Details:
Fruquintinib is a highly selective and potent oral inhibitor of VEGFR-1, -2 and -3. VEGFR inhibitors play a pivotal role in blocking tumor angiogenesis. Fruquintinib was designed to improve kinase selectivity to minimize off-target toxicities, improve tolerability.
Lead Product(s): Fruquintinib
Therapeutic Area: Oncology Product Name: Elunate
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Eli Lilly
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 08, 2022
Details:
Fruquintinib is a highly selective and potent oral inhibitor of VEGFR-1, -2 and -3. VEGFR inhibitors play a pivotal role in blocking tumor angiogenesis. ELUNATE® will become the first homegrown innovative oncology drug to be marketed in Macau based on its approval by the NMPA.
Lead Product(s): Fruquintinib
Therapeutic Area: Oncology Product Name: Elunate
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 01, 2022
Details:
Elunate (Fruquintinib), an investigational product for the treatment of patients with metastatic colorectal cancer met primary endpoint of the study, overall survival achieved.
Lead Product(s): Fruquintinib
Therapeutic Area: Oncology Product Name: Elunate
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 09, 2021
Details:
As per the agreement, SULANDA® will enter the NRDL, along with the renewal of ELUNATE®. The NRDL has made it possible for novel therapies to gain wide reach across the country for diseases with large patient populations.
Lead Product(s): Fruquintinib
Therapeutic Area: Oncology Product Name: Elunate
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: National Healthcare Security Administration
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement December 03, 2021
Details:
This is an open-label, multi-center, non-randomized study to assess the safety and efficacy of fruquintinib in combination with tislelizumab in patients with locally advanced or metastatic TNBC or advanced EC.
Lead Product(s): Fruquintinib,Tislelizumab
Therapeutic Area: Oncology Product Name: Elunate
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 26, 2021
Details:
Fruquintinib is a highly selective and potent oral inhibitor of vascular endothelial growth factor receptor (“VEGFR”) 1/2/3. Fruquintinib was approved by the China National Medical Products Administration (“NMPA”) in September 2018 under the brand name Elunate®.
Lead Product(s): Fruquintinib
Therapeutic Area: Oncology Product Name: Elunate
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Undisclosed
Deal Size: $104.0 million Upfront Cash: Undisclosed
Deal Type: Public Offering June 18, 2021
Details:
The agreement will aid in company's business growth as it looks to ramp up its oncology revenues from ELUNATE®, SULANDA® and the potential upcoming approval of savolitinib, likely to be a first-in-class selective c-MET inhibitor in China.
Lead Product(s): Fruquintinib
Therapeutic Area: Oncology Product Name: Elunate
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Baring Private Equity Asia
Deal Size: $100.0 million Upfront Cash: Undisclosed
Deal Type: Agreement April 08, 2021
Details:
FRESCO-2 is a randomized, double-blind, placebo-controlled, multicenter trial being conducted in patients with metastatic CRC. The primary endpoint of the study is overall survival. This large phase III trial will be enrolled in approximately 130 sites in 10 countries.
Lead Product(s): Fruquintinib
Therapeutic Area: Oncology Product Name: Elunate
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 04, 2020
Details:
Under the terms of the 2020 Amendment, Lilly will maintain the exclusive commercialization rights, and as a consequence, will continue to consolidate the sales of Elunate® in China. Chi-Med will collaborate with Lilly in commercializing Elunate® across China.
Lead Product(s): Fruquintinib
Therapeutic Area: Oncology Product Name: Elunate
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Eli Lilly
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration July 28, 2020
Details:
Fast Track Designation has been granted for the development of fruquintinib, for the treatment of patients with metastatic colorectal cancer who have been previously treated with fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy.
Lead Product(s): Fruquintinib
Therapeutic Area: Oncology Product Name: HMPL-013
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 20, 2020
Details:
FRUTIGA is a Phase III trial in China of fruquintinib in combination with paclitaxel (Taxol®) in the treatment of patients with advanced gastric adenocarcinoma or gastroesophageal junction (“GEJ”) adenocarcinoma who have progressed after first-line standard chemotherapy.
Lead Product(s): Fruquintinib,Paclitaxel
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 04, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
